bpc-157 arthritis evidence BPC-157: What It Is, What We Know, and Why Its Use for Remains Unproven BPC-157 For Knee Pain: Early

The soft-tissue evidence for both compounds is overwhelmingly rodent and cell-culture

Shim T, Strum DP, Mudry A, Monfared A

That can introduce variability such as: This is one of the biggest distinctions between clinical peptide therapy and what is available online

SubQ effects may take longer

Vitamins in tablet or capsule form may remain potent for several years

BPC-157 is most often considered when: Recovery from a musculoskeletal injury has stalled beyond the expected timeline Inflammation appears to be a persistent driver rather than an acute protective response Gut lining integrity is a concern as part of a broader inflammatory or digestive picture The patient is a reasonable candidate for physician-supervised peptide therapy based on health history and risk profile It is not appropriate when there is an unresolved structural question that imaging should answer first, when there are acute red flag symptoms warranting urgent evaluation, or when the individual is hoping a peptide will substitute for rehabilitation and load management